Muriel A. Adank

12.2k total citations · 1 hit paper
32 papers, 584 citations indexed

About

Muriel A. Adank is a scholar working on Genetics, Cancer Research and Molecular Biology. According to data from OpenAlex, Muriel A. Adank has authored 32 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Genetics, 14 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Muriel A. Adank's work include BRCA gene mutations in cancer (26 papers), Cancer Genomics and Diagnostics (11 papers) and DNA Repair Mechanisms (7 papers). Muriel A. Adank is often cited by papers focused on BRCA gene mutations in cancer (26 papers), Cancer Genomics and Diagnostics (11 papers) and DNA Repair Mechanisms (7 papers). Muriel A. Adank collaborates with scholars based in Netherlands, United States and United Kingdom. Muriel A. Adank's co-authors include Klaartje van Engelen, Nienke M. Nota, Koen M.A. Dreijerink, Ellis Barbé, Inge R. Konings, Chantal M Wiepjes, Christel J.M. de Blok, Martin den Heijer, Quinten Waisfisz and Saskia E. van Mil and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Muriel A. Adank

29 papers receiving 578 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

2019 238 citations Christel J.M. de Blok, Chantal M Wiepjes et al. BMJ profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Muriel A. Adank Netherlands	12	321	146	144	136	113	32	584
Sara Pirzadeh‐Miller United States	9	318 1.0×	47 0.3×	14 0.1×	67 0.5×	107 0.9×	25	410
Shanna Gustafson United States	12	290 0.9×	74 0.5×	7 0.0×	95 0.7×	173 1.5×	16	636
Emily Glogowski United States	14	172 0.5×	29 0.2×	7 0.0×	117 0.9×	88 0.8×	27	530
Elaine Hiller United States	6	393 1.2×	51 0.3×	12 0.1×	93 0.7×	140 1.2×	9	526
Deborah J. Goldfrank United States	13	146 0.5×	53 0.4×	21 0.1×	45 0.3×	46 0.4×	28	520
Bronson D. Riley United States	7	426 1.3×	74 0.5×	12 0.1×	72 0.5×	114 1.0×	8	604
Irmgard Nippert Germany	14	381 1.2×	128 0.9×	8 0.1×	74 0.5×	41 0.4×	44	592
Katherine Hicks-Courant United States	8	162 0.5×	133 0.9×	10 0.1×	42 0.3×	169 1.5×	17	420
Carmel Malone Ireland	11	196 0.6×	70 0.5×	23 0.2×	151 1.1×	280 2.5×	18	655
Elizabeth Cathcart-Rake United States	11	48 0.1×	74 0.5×	113 0.8×	26 0.2×	54 0.5×	56	466

Countries citing papers authored by Muriel A. Adank

Since Specialization

Citations

This map shows the geographic impact of Muriel A. Adank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muriel A. Adank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muriel A. Adank more than expected).

Fields of papers citing papers by Muriel A. Adank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muriel A. Adank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muriel A. Adank. The network helps show where Muriel A. Adank may publish in the future.

Co-authorship network of co-authors of Muriel A. Adank

This figure shows the co-authorship network connecting the top 25 collaborators of Muriel A. Adank. A scholar is included among the top collaborators of Muriel A. Adank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muriel A. Adank. Muriel A. Adank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hollema, Harry, Marise M. Wagner, Helena C. van Doorn, et al.. (2024). High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. JNCI Journal of the National Cancer Institute. 117(4). 719–727. 2 indexed citations

Schaapveld, Michael, Marjoleine F. Broekema, Margriet Collée, et al.. (2024). Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families. Genetics in Medicine. 26(9). 101171–101171. 2 indexed citations

Adank, Muriel A., Rosa de Groot, Christi J. van Asperen, et al.. (2024). Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2. BMJ Open. 14(10). e086688–e086688.

Cajal, Teresa Ramón y, Muriel A. Adank, J. Margriet Collée, et al.. (2023). The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. The Breast. 73. 103611–103611. 3 indexed citations

Smid, Marcel, Marjanka K. Schmidt, Wendy J. C. Prager‐van der Smissen, et al.. (2023). Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile. Breast Cancer Research. 25(1). 53–53. 5 indexed citations

Menko, Fred H., Kim Monkhorst, Frans B.L. Hogervorst, et al.. (2022). Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation. Critical Reviews in Oncology/Hematology. 176. 103642–103642. 6 indexed citations

Heemskerk-Gerritsen, B.A.M., Ewout W. Steyerberg, Michael Hauptmann, et al.. (2021). Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. The Breast. 61. 98–107. 5 indexed citations

Giardiello, Daniele, Ewout W. Steyerberg, Michael Hauptmann, et al.. (2020). Abstract P5-07-12: Prediction and clinical utility of a contralateral breast cancer risk model. Cancer Research. 80(4_Supplement). P5–7. 1 indexed citations

Blok, Christel J.M. de, Chantal M Wiepjes, Nienke M. Nota, et al.. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 365. l1652–l1652. 238 indexed citations breakdown →

10.

Rijken, Johannes A., Muriel A. Adank, Arjan W.J. Hoksbergen, et al.. (2018). A novel succinate dehydrogenase subunit B germline variant associated with head and neck paraganglioma in a Dutch kindred: A family‐based study. Clinical Otolaryngology. 43(3). 841–845. 3 indexed citations

11.

Moghadasi, Setareh, Luc Janssen, Mar Rodríguez‐Girondo, et al.. (2017). Performance of BRCA1/2 mutation prediction models in male breast cancer patients. Clinical Genetics. 93(1). 52–59. 3 indexed citations

12.

Tuin, Karin van der, Carli M.J. Tops, Muriel A. Adank, et al.. (2017). CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 102(12). 4534–4540. 62 indexed citations

13.

Vos, Janet R., Jan C. Oosterwijk, Cora M. Aalfs, et al.. (2016). Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 25(8). 1251–1258. 5 indexed citations

14.

Doorn, Helena C. van, Marian J.E. Mourits, Marc van Beurden, et al.. (2016). Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer. 115(10). 1174–1178. 3 indexed citations

15.

Adank, Muriel A., Frederik J. Hes, Wendy A.G. van Zelst–Stams, et al.. (2015). CHEK2-mutatie in Nederlandse borstkankerfamilies: uitbreiding van de genetische diagnostiek op borstkanker.. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 159(45). 1 indexed citations

16.

Wely, Madelon van, Frank J. Broekmans, Thea M. Mooij, et al.. (2014). BRCA1/2 mutation carriers do not have earlier natural menopause compared to proven non-carriers: report from the Dutch hereditary breast and ovarian cancer study group (HEBON). University of Groningen research database (University of Groningen / Centre for Information Technology). 1 indexed citations

17.

Vencken, P.M.L.H., Welmoed Reitsma, Mieke Kriege, et al.. (2013). Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Annals of Oncology. 24(8). 2036–2042. 16 indexed citations

18.

Adank, Muriel A., Senno Verhoef, Rogier A. Oldenburg, et al.. (2013). Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases. European Journal of Cancer. 49(8). 1993–1999. 13 indexed citations

19.

Mil, Saskia E. van, Gerry P. Crossan, Nelly Sabbaghian, et al.. (2012). Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases. Human Mutation. 34(1). 70–73. 15 indexed citations

20.

Adank, Muriel A., Heidi Segers, Saskia E. van Mil, et al.. (2010). Fanconi anemia gene mutations are not involved in sporadic Wilms tumor. Pediatric Blood & Cancer. 55(4). 742–744. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact